Fasting Glucose: Which Tests to Order Alongside

Why a Fasting Glucose Alone Is Not Enough

Fasting plasma glucose (FPG) captures a single snapshot of blood sugar after an 8 to 12 hour fast. It is cheap, widely available, and recommended by the USPSTF for screening adults aged 35 to 70 with overweight or obesity. But that single number has real blind spots.

A 2018 analysis published in The Lancet found that relying on FPG alone missed roughly 46% of diabetes cases that would have been detected by a 2-hour oral glucose tolerance test (OGTT) [1]. The reason is straightforward: FPG reflects hepatic glucose output overnight. It tells you nothing about how the pancreas handles a carbohydrate load during the day, how much insulin was required to achieve that fasting number, or whether the patient's average glucose has been drifting upward for months.

The American Diabetes Association (ADA) Standards of Care 2024 recommends using FPG in conjunction with HbA1c or an OGTT, not as a standalone diagnostic. This is especially true for patients being evaluated for GLP-1 receptor agonist therapy or testosterone replacement, where baseline metabolic status directly informs dosing and monitoring protocols.

Ordering the right companion tests turns a $10 blood draw into a metabolic map. The sections below cover each recommended add-on, what it reveals that glucose alone cannot, and the specific clinical scenarios where it matters most.

HbA1c: The 90-Day Average

HbA1c should be on every fasting glucose order. It measures the percentage of hemoglobin molecules glycated by prolonged glucose exposure, producing an average over the prior 8 to 12 weeks. The ADA diagnostic thresholds are clear: below 5.7% is normal, 5.7% to 6.4% is prediabetes, and 6.5% or higher on two tests confirms diabetes [2].

Where HbA1c adds value is in catching the patients whose fasting glucose looks reassuring. A person can wake up with a glucose of 94 mg/dL yet carry an HbA1c of 6.1% because of post-meal glucose spikes that fasting draws never detect. The Diabetes Prevention Program (DPP) trial (N=3,234) demonstrated that individuals in this "normal fasting, elevated HbA1c" category had a 58% reduction in diabetes incidence with lifestyle intervention, confirming that this subgroup benefits enormously from early identification [3].

There are populations where HbA1c is less reliable. Hemoglobin variants (sickle cell trait, thalassemia), chronic kidney disease with erythropoietin use, and recent blood transfusion can all skew results. In these cases, the ADA recommends FPG or OGTT as the primary test rather than HbA1c [2]. Clinicians ordering labs for patients of African, Mediterranean, or Southeast Asian descent should note hemoglobinopathy status and consider a fructosamine assay if results seem discordant.

Fasting Insulin and HOMA-IR: Finding Resistance Early

Fasting glucose tells you what the blood sugar is. Fasting insulin tells you what the body had to do to get it there. That difference matters. A fasting glucose of 92 mg/dL with a fasting insulin of 5 µIU/mL represents healthy metabolism. The same glucose with an insulin of 22 µIU/mL signals that the pancreas is working overtime to maintain normal blood sugar, a condition called compensatory hyperinsulinemia.

The Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) quantifies this relationship: fasting glucose (mg/dL) multiplied by fasting insulin (µIU/mL), divided by 405. A HOMA-IR below 1.0 is considered optimal. Values above 2.5 indicate probable insulin resistance, and values above 5.0 suggest severe resistance [4]. The Endocrine Society's 2022 clinical practice guideline on metabolic syndrome specifically lists HOMA-IR as a recommended tool for risk stratification in patients with obesity.

For HealthRX patients starting GLP-1 medications, baseline HOMA-IR provides a measurable anchor for treatment response. A patient whose HOMA-IR drops from 4.8 to 1.9 over 16 weeks has objective evidence that insulin sensitivity has improved, independent of the scale. For TRT candidates, testosterone deficiency itself worsens insulin resistance. A 2016 meta-analysis of 11 RCTs (N=1,714) published in The Journal of Clinical Endocrinology & Metabolism found that testosterone therapy reduced HOMA-IR by 0.57 units (95% CI: 0.32 to 0.82) [5].

The test requires nothing beyond adding insulin to the same fasting blood draw. Cost at most commercial labs ranges from $15 to $40.

Lipid Panel: The Metabolic Neighbor

Dyslipidemia and impaired glucose metabolism travel together. The ADA 2024 Standards of Care report that roughly 70% of adults with prediabetes have at least one lipid abnormality, most commonly elevated triglycerides and low HDL cholesterol [6]. This pattern, sometimes called atherogenic dyslipidemia, is driven by the same insulin resistance that pushes fasting glucose upward.

A standard lipid panel includes total cholesterol, LDL, HDL, and triglycerides. Ordering it alongside fasting glucose captures both arms of cardiometabolic risk in a single draw. The triglyceride-to-HDL ratio (TG/HDL) is itself an independent proxy for insulin resistance. A TG/HDL ratio above 3.0 in non-Hispanic white populations (or above 2.0 in African American populations) correlates with elevated HOMA-IR values [7].

For patients on GLP-1 receptor agonists, baseline lipid values also set the reference for treatment benefit. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg reduced triglycerides by 22% and increased HDL by 3% at 68 weeks compared with placebo [8]. Capturing pre-treatment lipid values allows clinicians to demonstrate these cardiovascular benefits at follow-up.

The ADA and the American Association of Clinical Endocrinology (AACE) both recommend lipid screening at the time of diabetes or prediabetes diagnosis and annually thereafter.

Comprehensive Metabolic Panel: Kidney and Liver Context

A comprehensive metabolic panel (CMP) adds 14 analytes to the basic glucose draw, including serum creatinine, blood urea nitrogen, ALT, AST, albumin, bilirubin, and electrolytes. Two of these groupings have direct relevance to anyone whose fasting glucose is outside the normal range.

Kidney function comes first. Diabetic kidney disease affects approximately 40% of people with type 2 diabetes over their lifetime, according to CDC surveillance data [9]. Estimated glomerular filtration rate (eGFR), calculated from serum creatinine, is essential for two reasons: it stages existing renal disease, and it determines whether metformin or certain GLP-1 agonists can be safely prescribed. Semaglutide does not require dose adjustment for mild-to-moderate renal impairment, but liraglutide requires caution at eGFR below 15 mL/min/1.73m² per the FDA prescribing information [10].

Liver enzymes (ALT and AST) are the second priority. Non-alcoholic fatty liver disease (now termed metabolic dysfunction-associated steatotic liver disease, or MASLD) is present in up to 70% of patients with type 2 diabetes [11]. A baseline ALT above 30 U/L in men or above 19 U/L in women should prompt further evaluation. GLP-1 receptor agonists have shown liver-protective effects. The LEAN trial (N=52) found that liraglutide 1.8 mg daily resolved NASH (confirmed on biopsy) in 39% of patients versus 9% on placebo (P=0.019) at 48 weeks [12].

A CMP costs between $10 and $30 at most labs and can be drawn from the same tube as fasting glucose.

C-Peptide: Beta-Cell Reserve

C-peptide is co-secreted with insulin in a 1:1 molar ratio but has a longer half-life (approximately 30 minutes versus 5 minutes for insulin), making it a more stable marker of endogenous insulin production. Ordering C-peptide alongside fasting glucose answers a question that glucose alone never can: how much insulin is the pancreas actually making?

This distinction is most relevant in two scenarios. First, in adults presenting with new-onset hyperglycemia, a low C-peptide (below 0.6 ng/mL fasting) raises suspicion for latent autoimmune diabetes of adults (LADA), which requires insulin therapy rather than oral agents or GLP-1 agonists. The Endocrine Society estimates that LADA accounts for 5% to 10% of adults initially diagnosed with type 2 diabetes [13].

Second, in patients already on insulin or considering insulin initiation, C-peptide helps quantify residual beta-cell function. A 2020 study in Diabetes Care (N=1,549) demonstrated that patients with type 2 diabetes and preserved C-peptide (above 1.0 ng/mL) had significantly fewer hypoglycemic events on insulin therapy compared with those whose C-peptide had declined below that threshold [14].

For GLP-1 prescribing, C-peptide also informs expected efficacy. GLP-1 agonists work partly by potentiating glucose-dependent insulin secretion. Patients with very low beta-cell reserve may see less glycemic benefit, though weight-loss and cardiovascular effects remain.

Oral Glucose Tolerance Test: The Deeper Look

The 2-hour 75g oral glucose tolerance test (OGTT) remains the gold standard for diagnosing impaired glucose tolerance (IGT), a condition that fasting glucose and HbA1c may both miss. The patient drinks a standardized 75g glucose solution, and blood is drawn at baseline and at 120 minutes. A 2-hour value of 140 to 199 mg/dL indicates IGT; 200 mg/dL or above confirms diabetes [2].

The OGTT captures postprandial glucose handling, which deteriorates earlier in the disease trajectory than fasting glucose. The DECODE study (N=22,514) showed that 2-hour glucose was a stronger predictor of cardiovascular mortality than fasting glucose, even after adjustment for traditional risk factors [15]. This finding is directly relevant for patients in the cardiometabolic risk window who may have a "normal" FPG but whose post-meal glucose regularly exceeds 180 mg/dL.

The test does have practical limitations. It requires a 2-hour in-clinic visit, patients must fast for 8 to 12 hours beforehand, and results can vary with stress, illness, and physical activity in the preceding days. For routine screening, the ADA considers HbA1c plus FPG an acceptable alternative. The OGTT is specifically warranted when FPG and HbA1c give discordant results (for example, FPG of 102 mg/dL but HbA1c of 5.4%), when screening for gestational diabetes, or when clinical suspicion for diabetes is high despite normal fasting values.

The ACOG recommends a one-step 75g OGTT or a two-step approach (50g screen followed by 100g diagnostic test) for all pregnant patients at 24 to 28 weeks of gestation [16].

Additional Add-Ons for Specific Populations

Beyond the core panel (fasting glucose, HbA1c, fasting insulin, lipid panel, CMP, and C-peptide), certain patients benefit from targeted extras.

Thyroid-stimulating hormone (TSH). Hypothyroidism increases insulin resistance and raises LDL cholesterol. The American Thyroid Association recommends TSH screening in adults with new metabolic abnormalities [17]. Cost is typically $20 to $40.

Uric acid. Hyperuricemia correlates with insulin resistance and predicts incident type 2 diabetes. A meta-analysis of 11 prospective studies (N=42,834) found that each 1 mg/dL increase in serum uric acid raised diabetes risk by 17% (RR 1.17 to 95% CI 1.09 to 1.25) [18].

High-sensitivity C-reactive protein (hs-CRP). While not a glucose marker, hs-CRP captures systemic inflammation that often accompanies metabolic syndrome. The JUPITER trial (N=17,802) demonstrated that statin therapy in patients with elevated hs-CRP (above 2.0 mg/L) reduced cardiovascular events by 44%, regardless of LDL level [19]. For patients with prediabetes and elevated hs-CRP, this may shift the conversation toward earlier pharmacologic intervention.

Testosterone (total and free). In men with fasting glucose in the prediabetes or diabetes range, testosterone testing is warranted. The Endocrine Society clinical practice guideline on male hypogonadism notes that type 2 diabetes is associated with low testosterone in 25% to 40% of affected men [20]. Because both conditions worsen the other, identifying both simultaneously allows integrated treatment.

How to Lower Fasting Glucose: Evidence-Based Interventions

For patients whose fasting glucose lands in the 100 to 125 mg/dL prediabetes range, the evidence strongly favors structured lifestyle intervention as the first step. The Diabetes Prevention Program trial showed that 150 minutes per week of moderate physical activity combined with 7% body weight loss reduced progression to type 2 diabetes by 58% over 2.8 years [3]. In participants over age 60, the reduction reached 71%.

Specific dietary patterns make a measurable difference. A 2019 meta-analysis in The BMJ (N=48,066 across 9 trials) found that Mediterranean-style diets reduced fasting glucose by an average of 3.9 mg/dL compared with control diets [21]. Time-restricted eating (confining food intake to an 8 to 10 hour window) reduced fasting glucose by 3 to 7 mg/dL in several pilot studies, though larger RCTs are still underway.

Pharmacologically, metformin remains the first-line agent for diabetes prevention in high-risk patients. The DPP showed metformin 850 mg twice daily reduced diabetes incidence by 31% versus placebo [3]. For patients with BMI of 30 or above, GLP-1 receptor agonists offer dual benefits. Dr. Robert Gabbay, Chief Scientific and Medical Officer of the ADA, stated in a 2023 interview: "GLP-1 receptor agonists represent the most significant advance in type 2 diabetes pharmacotherapy in the last two decades, particularly for patients who also need weight management."

Sleep duration matters too. A 2023 study in Annals of Internal Medicine (N=38) found that extending sleep from 6.2 to 7.7 hours per night reduced 24-hour mean glucose by approximately 5 mg/dL within two weeks, without any dietary or exercise changes [22].

Building the Order Set: A Practical Checklist

A cost-effective paired order for any patient whose fasting glucose prompts clinical attention includes these tests, drawn from a single morning fasting blood sample:

1. Fasting plasma glucose (confirmatory or baseline)
2. HbA1c
3. Fasting insulin (for HOMA-IR calculation)
4. Comprehensive metabolic panel (includes creatinine, ALT, AST, electrolytes)
5. Lipid panel (total cholesterol, LDL, HDL, triglycerides)
6. C-peptide (if new-onset hyperglycemia or considering GLP-1 therapy)

Add-ons based on clinical context: TSH, uric acid, hs-CRP, testosterone (men), or OGTT (discordant results or pregnancy screening). Total out-of-pocket cost for the core six tests at commercial labs typically falls between $75 and $150 without insurance.

The AACE 2023 Consensus Statement on Comprehensive Type 2 Diabetes Management recommends reassessing HbA1c every 3 months for patients on new therapy and fasting glucose at each visit until targets are achieved [23]. As Dr. Paul Jellinger, past president of AACE, noted: "The era of treating glucose in isolation is over. Every glucose abnormality exists within a metabolic context that includes lipids, liver health, kidney function, and hormonal balance."

Recheck fasting insulin and recalculate HOMA-IR at 12 to 16 weeks after initiating any metabolic intervention, whether lifestyle, GLP-1 therapy, or TRT, to confirm that insulin sensitivity is improving in parallel with glucose values.